Skip to main
AARD
AARD logo

AARD Stock Forecast & Price Target

AARD Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 57%
Buy 43%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Aardvark Therapeutics Inc. presents a strong investment case due to its innovative focus on targeting Bitter Taste Receptors (TAS2Rs) for metabolic diseases, particularly with its lead product candidate, ARD-101, which is currently in Phase 3 trials for hyperphagia linked to Prader-Willi Syndrome (PWS). The company's prospects are further bolstered by the significant market demand for effective obesity treatments, evidenced by high valuations and premiums in the sector, which highlights the lucrative potential of its niche. Additionally, the strategic appeal of ARD-101 in offering an orally bioavailable weight loss option positions Aardvark therapeutically and financially favorably within the burgeoning obesity therapeutics market.

Bears say

The analysis identifies significant risks associated with Aardvark Therapeutics Inc's stock outlook, particularly relating to clinical trial outcomes. The company is heavily reliant on the success of its Phase 3 HERO trial for ARD-101, with potential adverse results posing serious implications for its market position and regulatory approval timeline. Additionally, there are concerns regarding possible partnership risks, macroeconomic factors, and long-term dilution, all of which could adversely affect investor sentiment and the company's financial stability.

AARD has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 57% of analysts recommend a Strong Buy, 43% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Aardvark Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Aardvark Therapeutics Inc (AARD) Forecast

Analysts have given AARD a Strong Buy based on their latest research and market trends.

According to 7 analysts, AARD has a Strong Buy consensus rating as of Oct 29, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $31.43, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $31.43, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Aardvark Therapeutics Inc (AARD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.